232 related articles for article (PubMed ID: 29126030)
21. Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients.
Nguyen LT; Ramanathan M; Weinstock-Guttman B; Baier M; Brownscheidle C; Jacobs LD
J Neurol Sci; 2003 May; 209(1-2):93-9. PubMed ID: 12686409
[TBL] [Abstract][Full Text] [Related]
22. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
23. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L
Mult Scler; 2014 Jun; 20(7):877-81. PubMed ID: 24293455
[TBL] [Abstract][Full Text] [Related]
24. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
25. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
[TBL] [Abstract][Full Text] [Related]
26. Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial.
Sanoobar M; Eghtesadi S; Azimi A; Khalili M; Khodadadi B; Jazayeri S; Gohari MR; Aryaeian N
Nutr Neurosci; 2015 May; 18(4):169-76. PubMed ID: 24621064
[TBL] [Abstract][Full Text] [Related]
27. Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis.
Montalban X; Comi G; Antel J; O'Connor P; de Vera A; Cremer M; Sfikas N; von Rosenstiel P; Kappos L
J Neurol; 2015 Dec; 262(12):2627-34. PubMed ID: 26338810
[TBL] [Abstract][Full Text] [Related]
28. Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study.
Laribi B; Sahraian MA; Shekarabi M; Emamnejad R; Marzban M; Sadaghiani S; Izad M
Iran J Allergy Asthma Immunol; 2018 Aug; 17(4):346-360. PubMed ID: 30537798
[TBL] [Abstract][Full Text] [Related]
29. Oxidative stress activity of fingolimod in multiple sclerosis.
Yevgi R; Demir R
Clin Neurol Neurosurg; 2021 Mar; 202():106500. PubMed ID: 33508648
[TBL] [Abstract][Full Text] [Related]
30. Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial.
Hunter SF; Agius M; Miller DM; Cutter G; Barbato L; McCague K; Meng X; Agashivala N; Chin P; Hollander E
J Neurol Sci; 2016 Jun; 365():190-8. PubMed ID: 27206905
[TBL] [Abstract][Full Text] [Related]
31. Effects of adjunct glucosamine sulfate on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized, placebo-controlled trial.
Shaygannejad V; Janghorbani M; Savoj MR; Ashtari F
Neurol Res; 2010 Nov; 32(9):981-5. PubMed ID: 20223094
[TBL] [Abstract][Full Text] [Related]
32. The effects of fish oil supplementation on markers of inflammation in chronic kidney disease patients.
Deike E; Bowden RG; Moreillon JJ; Griggs JO; Wilson RL; Cooke M; Shelmadine BD; Beaujean AA
J Ren Nutr; 2012 Nov; 22(6):572-7. PubMed ID: 22285316
[TBL] [Abstract][Full Text] [Related]
33. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
[TBL] [Abstract][Full Text] [Related]
34. Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial.
Toghianifar N; Ashtari F; Zarkesh-Esfahani SH; Mansourian M
J Neuroimmunol; 2015 Aug; 285():125-8. PubMed ID: 26198928
[TBL] [Abstract][Full Text] [Related]
35. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
[TBL] [Abstract][Full Text] [Related]
36. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA
J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498
[TBL] [Abstract][Full Text] [Related]
37. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
[TBL] [Abstract][Full Text] [Related]
38. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D
Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350
[TBL] [Abstract][Full Text] [Related]
39. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses.
Chinea Martinez AR; Correale J; Coyle PK; Meng X; Tenenbaum N
Adv Ther; 2014 Oct; 31(10):1072-81. PubMed ID: 25245812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
